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Background: Intra-peritoneal adhesions are frequent following abdominal surgery and are the most common
cause of small bowel obstructions. A hyaluronic acid/carboxymethylcellulose (HA/CMC) film adhesion barrier has
been shown to reduce adhesion formation in abdominal surgery. An HA/CMC powder formulation was developed
for application during laparoscopic procedures.
Methods: This was an exploratory, prospective, randomised, single-blind, parallel-group, Phase IIIb, multicentre study
conducted at 15 hospitals in France to assess the safety of HA/CMC powder versus no adhesion barrier following
laparoscopic colorectal surgery. Subjects ≥18 years of age who were scheduled for colorectal laparoscopy
(Mangram contamination class I‒III) within 8 weeks of selection were eligible, regardless of aetiology. Participants
were randomised 1:1 to the HA/CMC powder or no adhesion barrier group using a centralised randomisation list.
Patients assigned to HA/CMC powder received a single application of 1 to 10 g on adhesion-prone areas. In the no
adhesion barrier group, no adhesion barrier or placebo was applied. The primary safety assessments were the
incidence of adverse events, serious adverse events, and surgical site infections (SSIs) for 30 days following surgery.
Between-group comparisons were made using Fisher’s exact test.
Results: Of those randomised to the HA/CMC powder (n = 105) or no adhesion barrier (n = 104) groups, one
patient in each group discontinued prior to the study end (one death in each group). Adverse events were more
frequent in the HA/CMC powder group versus the no adhesion barrier group (63% vs. 39%; P <0.001), as were
serious adverse events (28% vs. 11%; P <0.001). There were no statistically significant differences between the HA/
CMC powder group and the no adhesion barrier group in SSIs (21% vs. 14%; P = 0.216) and serious SSIs (12% vs.
9%; P = 0.38), or in the most frequent serious SSIs of pelvic abscess (5% and 2%; significance not tested),
anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).
Conclusions: This exploratory study found significantly higher rates of adverse events and serious adverse events
in the HA/CMC powder group compared with the no adhesion barrier group in laparoscopic colorectal resection.
Trial registration: ClinicalTrials.gov NCT00813397. Registered 19 December 2008.
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Intra-peritoneal adhesions are estimated to occur after
93% to 100% of upper abdominal laparotomies and after
67% to 93% of lower abdominal laparotomies [1]. Ad-
hesions form as a result of surgical trauma or infection/
inflammation, and comprise fibrous scar tissue that ab-
normally connects tissues and organs [2]. They are the
most common cause of small bowel obstructions [3-6]
and are associated with infertility and possibly chronic
pain. Adhesions may also prolong operating time in sub-
sequent surgery, and cause complications such as unin-
tentional enterotomy [2,6-8].
There is no effective treatment for adhesions, and sur-
gery to deal with the consequences of adhesions, such as
small bowel obstruction, often results in further adhe-
sion formation [1,2]. Adhesion prevention should there-
fore be considered the best management strategy [2,9],
although this is not widely demonstrated in the lite-
rature. A good surgical technique (e.g., minimal tissue
trauma, avoiding introduction of foreign materials) can
reduce adhesion formation, but is not sufficient for pre-
vention [2,9]. Adhesions may be reduced by using lapa-
roscopy versus open surgery [10-12], which results in a
reduction in adhesion-related complications, such as
small bowel obstruction, but does not totally prevent ad-
hesion formation [6]. A number of anti-adhesion pro-
ducts are available for adjuvant use during surgery, with
various formulations including films, fabrics, gels, and
fluids. These products act as a temporary mechanical
barrier to separate organs and tissues for a short time
while healing takes place. Despite the number of agents
available worldwide, few have demonstrated efficacy in re-
ducing post-surgical adhesions, and limited conclusions
can be drawn on the effect of reducing adhesions, as no
agent has been shown to improve the myriad negative
outcomes commonly associated with adhesions [13].
In abdominal surgery, a hyaluronic acid/carboxymeth-
ylcellulose (HA/CMC) film adhesion barrier has been
shown to reduce adhesion formation with a favourable
safety profile [13-17]. A powder formulation of HA/
CMC (HA/CMC powder; Sepraspray™ Adhesion Barrier,
Genzyme Corp., Cambridge, MA, USA) was developed
for application during laparoscopic procedures. Prec-
linical animal models indicated that this formulation was
effective in reducing adhesion formation and did not
disrupt normal wound healing [18,19]. In a randomised
pilot study in women undergoing laparoscopic myomec-
tomy, there was a trend towards a reduction in adhe-
sions with HA/CMC powder versus no adhesion barrier,
with a favourable safety profile [20]. The primary objec-
tive of this study was to assess the safety of HA/CMC
powder versus no adhesion barrier following laparo-
scopic colorectal and/or small bowel surgery (high risk
for morbidity [21]), as determined by the incidence ofadverse events, serious adverse events, superficial surgi-
cal site infections (SSIs) and deep SSIs, such as fistula,
sepsis, abscess, and peritonitis.
Methods
This was an exploratory, prospective, randomised, single-
blind, parallel-group, Phase IIIb, multicentre study con-
ducted at 15 hospitals in France (ClinicalTrials.gov
Identifier: NCT00813397). The study comprised a selec-
tion visit 1 to 56 days prior to the planned surgery (Day 0)
and two postoperative follow-up assessments (day of
discharge or 7 ± 3 days post-surgery, and end-of-study
assessment 28 to 35 days post-surgery). This follow-up
duration was based on postoperative guidelines on infec-
tions [22] and the knowledge that HA/CMC is resorbed
from the peritoneal cavity within 7 days and fully elimi-
nated from the body in <28 days [23].
The study was carried out in compliance with the Dec-
laration of Helsinki and the principles of the French Good
Clinical Practice regulations/clinical research guidelines.
The protocol and patient consent forms were approved by
an independent ethics committee (reference number 208
R09, Sud-Méditerranée II, Marseille, France). All patients
signed an informed consent form. An independent review
committee of four independent experts was established to
provide real-time expert review of safety reports and as-
sess all safety data at study end.
Participants
Men and women ≥18 years of age were eligible if they
were scheduled to undergo a laparoscopic colorectal and/
or small intestine surgical resection of Mangram conta-
mination class I, II, or III [22] within 8 weeks of selection,
whatever the aetiology (including cancer). Participants
were also required to have an American Society of Anes-
thesiologists Physical Status Classification of P1, P2, or P3
and women of childbearing potential were required to use
an effective contraceptive method for 1 month after
randomisation. The principal exclusion criteria were can-
cer requiring chemotherapy and/or radiotherapy within
30 days prior to or after surgery; current abdominal ab-
scess and/or peritonitis; pregnancy; clinically significant
cardiovascular, hepatic, neurologic, psychiatric, endocrine,
or other major systemic disease that would interfere with
the study or jeopardize patient outcomes within 30 days;
and treatment with heparinic anticoagulants (except
prophylaxis for deep vein thrombosis).
Additional exclusion criteria applied at the time of
surgery were use of another medical device that may
interfere with the study (e.g., prosthetic stitch, biological
adhesive, haemostatic compress, surgical membrane, or
physical barrier to prevent adherence); infection dis-
covered in the abdominal cavity; change to Mangram
contamination class IV; and conversion to laparotomy
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standard laparoscopic approaches in colorectal surgery).
Treatment
Participants were randomised to the HA/CMC powder or
no adhesion barrier group during the planned surgical
procedure (Day 0) in a 1:1 ratio using a centralised
randomisation list and an automated Interactive Voice
Response System, following re-evaluation of their eligi-
bility. Patients were blinded to their randomisation group
throughout the study.
Patients assigned to HA/CMC powder received a single
application to adhesion-prone areas but not to anasto-
moses or sutures. HA/CMC powder was applied with a
single-use applicator attached to a sprayer to allow precise
application to the required sites while minimizing poten-
tial dispersion to other sites. The amount applied was at
the surgeon’s judgement, and ranged from 1 to 10 g, with
the maximum determined based on a previous study of
HA/CMC film [24]. In patients assigned to the no ad-
hesion barrier group, no adhesion barrier or placebo was
applied. In both groups, closure of trocar sites was per-
formed according to the normal routine of the surgeon;
peritoneal closure was not performed.
Safety assessments
The primary objective of this study was to compare the in-
cidence of adverse events, serious adverse events, super-
ficial (incisional) SSIs, and deep SSIs in the HA/CMC
powder and no adhesion barrier groups for 30 days fol-
lowing surgery. Any suspected intra-abdominal abscess
was investigated by CT-scan/MRI. Any suspicion of sepsis
was confirmed by at least one positive blood culture and
specific symptoms. Any suspicion of peritonitis was con-
firmed by positive bacterial cultures from peritoneal swabs
of drainage during interventional radiology or surgery. All
such SSIs were followed up until resolution. In the HA/
CMC powder group, the relationship of adverse events to
treatment was judged by investigators as not related, un-
likely, possibly, probably, or definitely related. Events that
were routinely observed during the postoperative period
(e.g., pain, nausea, vomiting) were not reported as an
adverse event unless they occurred with unusual severity
according to the investigator’s judgement, or required
unusual or specific management.
The duration of hospitalisation after surgery was noted
along with intraoperative parameters and perioperative
parameters. Exposure to HA/CMC powder was deter-
mined from the amount of powder applied (grams) and
duration of application (minutes).
Ease of use, manageability, and reliability assessments
Ease of use was evaluated by the surgeon using a 4-point
scale (1 = very difficult, 2 = difficult, 3 = easy, 4 = veryeasy). HA/CMC powder was considered manageable if
this item was scored 3 or 4. The ease of attaching the
applicator to the sprayer and introducing the HA/CMC
powder into the sprayer was assessed by the nurse in
charge of surgical instruments in the operating room
using the same 4-point scale. HA/CMC powder was
considered manageable if both items were scored 3 or 4.
Reliability was assessed by the surgeon based on the
ability to cover all target areas, apply a homogeneous
layer, and deliver the suitable amount of HA/CMC pow-
der using a 4-point scale (1 = very bad, 2 = bad, 3 = good,
4 = very good), with HA/CMC powder being considered
reliable if each item was scored 3 or 4.
Statistical analysis
As the study was exploratory, no sample size calculation
was performed. Safety analyses were performed on the
safety population, comprising all randomised patients
who underwent surgery. Surgical and ease of use ana-
lyses were performed on the intent-to-treat population,
described as all randomised patients who received treat-
ment during surgery as determined by randomisation.
Safety data are reported in summary tables and between-
group comparisons made using Fisher’s exact test. Descrip-
tive statistics are provided for ease of use, manageability,
and reliability.
A post-hoc analysis of risk factors for deep SSIs and
serious adverse events was carried out. Logistic regres-
sion was performed for each covariate. The univariate
model included treatment effect, covariate effect, and
the effect for the interaction between treatment and the
covariate. Covariates included gender, age, body mass
index, smoking status, smoking frequency, use of drains,
adhesiolysis, and type of anastomosis, among others. A
significance level of 0.10 (deep SSIs) or 0.20 (serious
adverse events) was used to select the individual covari-
ates to be included in the final multivariate model for
the backwards stepwise logistic regression analysis. The
odds ratio (OR) and 95% confidence intervals (CI) were
calculated.
Role of the sponsor
The study sponsor was involved in the design of the
study. Data were collected by investigators at each site.
Patient randomisation and data management were car-
ried out by a research organisation contracted by the
study sponsor. Together with the study investigators, the
sponsor participated in the analysis and interpretation of
data, the writing of the manuscript, and the decision to
submit the manuscript for publication.
Results
The study was carried out between September 2008 and
July 2009. Patient disposition is summarized in Figure 1.
Figure 1 Patient disposition. ITT, intent-to-treat.
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(n = 105) or the no adhesion barrier (n = 104) groups,
only one patient in each group discontinued prior to
study end (one death in each group). Patient characte-
ristics and medical history were similar (Table 1), except
for a lower frequency of patients with concomitant
allergic diseases (P = 0.031) and a higher frequency
of patients taking concomitant penicillin combinations
(significance not tested) in the HA/CMC powder group
versus no adhesion barrier. Previous or concomitant im-
munosuppressive drugs were taken by 7/105 (7%) pa-
tients in the HA/CMC powder group and 12/104 (12%)
patients in the no adhesion barrier group (P = 0.221),
and corticosteroids by 15/105 (14%) and 22/104 (21%)
patients, respectively (P = 0.193). Within the year prior
to study randomisation (but not within 30 days before
surgery), 10/105 (19%) of patients in the HA/CMC
powder group and 7/104 (15%) in the no adhesion bar-
rier group had received abdominal or pelvic radiotherapy
(P = 0.666), and 9/105 (17%) and 8/104 (17%), respec-
tively, had received chemotherapy (P = 0.958). Intra-
operative parameters were comparable between groups
(Table 2), although adhesiolysis (P = 0.073) and manual
anastomosis (P = 0.034) were performed more fre-
quently in the HA/CMC powder group.
There were no differences between the HA/CMC
powder and no adhesion barrier groups in perioperative
findings (Table 3) except for number of drains used
(P = 0.021) and mean duration of surgery (P = 0.419).Safety outcomes
Adverse events, serious adverse events, and deaths are
summarized in Table 4. One patient in each group had
an adverse event leading to death: septic shock stem-
ming from aspiration pneumonia in the HA/CMC pow-
der group, and septic shock and multiorgan failure in
the no adhesion barrier group; for the patient in the
HA/CMC powder group, the investigator assessed the
adverse event as not related to treatment.
The overall frequency of adverse events was sig-
nificantly higher in the HA/CMC powder versus the no
adhesion barrier group (66/105 [63%] vs. 41/104 [39%];
P <0.001). The overall frequency of serious adverse events
was significantly higher in the HA/CMC powder group
compared with the no adhesion barrier (P <0.001).
Overall, 10/105 (10%) patients in the HA/CMC powder
group experienced at least one adverse event that was
considered by the investigator as possibly, probably, or
definitely related to the investigational product: abdominal
pain (n = 2), flatulence (n =2), ileus (n = 1), impaired gas-
tric emptying (n = 1), intestinal obstruction (n = 1), ab-
dominal abscess (n = 2), intestinal abscess (n = 1), incision
site abscess (n = 1), anastomotic fistula (n = 1), incision
site haemorrhage (n = 1), and postoperative ileus (n = 1).
The frequency of treatment-related serious adverse events
in the HA/CMC powder group was 4% (4/105 patients),
and these were ileus (n = 1) and the SSIs of abdominal
abscess (n = 2), intestinal abscess (n = 1), incision site
abscess (n = 1), and anastomotic fistula (n = 1). As this
Table 1 Patient characteristics and medical history at baseline (intent-to-treat population)
HA/CMC powder (n = 105) No adhesion barrier (n = 104) P value
Age in years, mean ± SD 57.6 ± 16.3 56.1 ± 16.5 0.531
Men, n (%) 53 (50.5) 51 (49.0) 0.835
BMI in kg/m2, mean ± SD 24.7 ± 4.0 24.3 ± 4.2 0.451
Smoking history, n (%) 0.676
Current smoker 16 (15.8) 18 (17.8)
Ex-smoker 19 (18.8) 23 (22.8)
Non-smoker 66 (65.3) 60 (59.4)
Previous abdominal/pelvic surgery, n (%) 58 (55.2) 61 (58.7) 0.618
Diabetes, n (%) 10 (9.6) 5 (4.8) 0.180
Pre-operative diagnosis, n (%) 0.566
Cancer 48 (45.7) 44 (42.3)
Diverticulosis 27 (25.7) 36 (34.6)
Crohn’s disease 11 (10.5) 7 (6.7)
Ulcerative colitis 5 (4.8) 7 (6.7)
Polyp (no cancer) 5 (4.8) 5 (4.8)
Other 5 (4.8) 1 (1.0)
Endometriosis 2 (1.9) 3 (2.9)
Polyposis 2 (1.9) 1 (1.0)
ASA Physical Status classification, n (%) 0.537
P1 37 (35.2) 41 (39.4)
P2 60 (57.1) 52 (50.0)
P3 8 (7.6) 11 (10.6)
Concomitant diseases (≥20% patients in either group), n (%)
Gastrointestinal, hepatic 46 (43.8) 39 (37.5) 0.353
Cardiovascular 31 (29.5) 35 (33.7) 0.521
Metabolic, endocrine, nutritional 38 (36.2) 26 (25.0) 0.079
Allergic 18 (17.1) 31 (29.8) 0.031
Concomitant medications (≥10% patients in either group), n (%)
Heparin 51 (48.6) 47 (45.2) ND
Combination of penicillins* 17 (16.2) 9 (8.7) ND
*Including β-lactamase inhibitors.
ASA, American Society of Anesthesiologists; BMI, Body mass index; ND, Not determined.
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could not be reported in the no adhesion barrier group.
There was no relationship between the amount of HA/
CMC powder used and incidence of adverse events or ser-
ious adverse events (data not shown).
At least one SSI was experienced by 22/105 (21%) of
patients in the HA/CMC powder group versus 15/104
(14%) in the no adhesion barrier group (P = 0.216), and
at least one serious SSI by 13/105 (12%) versus 9/104
(9%), respectively (P = 0.38; Table 5). There were no
numeric differences between the HA/CMC powder and
the no adhesion barrier groups in the most frequently
reported serious SSIs of pelvic abscess (4.8% and 1.9%,
respectively), anastomotic fistula (2.9% and 3.8%), andperitonitis (1.9% and 2.9%; statistical significance not
tested).
In the HA/CMC powder group, the mean ± SD
amount of powder applied was 2.7 ± 1.4 g, with 40% of
patients receiving 4 to 6 g, 37% receiving 2 to 3 g, and
23% receiving only 1 g. The mean ± SD duration of ap-
plication was 5.6 ± 3.4 min. The mean ± SD duration of
hospitalisation after surgery was 9.7 ± 6.3 days in the
HA/CMC powder group compared with 7.5 ± 3.4 days in
the no adhesion barrier group (P = 0.009).
Adverse events by preoperative diagnosis are summa-
rized in Table 6. A greater frequency of adverse events
among patients with cancer was observed than in pa-
tients with other diagnoses in both groups; however, the
Table 2 Intra-operative parameters (intent-to-treat
population)
HA/CMC
powder (n = 105)
No adhesion
barrier (n = 104)
Adhesiolysis, n (%) 36 (34.3) 24 (23.1)
Type of resection, n (%)
Sigmoidectomy and/or
left colectomy
44 (41.9) 50 (48.1)
Proctectomy 21 (20.0) 25 (24.0)
Right ileocolectomy 31 (29.5) 20 (19.2)
Total proctocolectomy 5 (4.8) 3 (2.9)
Abdominoperineal
amputation
2 (1.9) 2 (1.9)




Left colectomy and small
intestine resection (ileum)
1 (1.0) 0
Anastomosis, n (%) 102 (97.1) 99 (95.2)
Manual 28 (27.5)* 15 (15.2)
Mechanical 74 (72.5) 84 (84.8)
Stomy, n (%) 27 (25.7) 23 (22.1)
Partial omentectomy, n (%) 12 (11.4) 12 (11.5)
Classification of surgical area
during surgery, n (%)
Clean – contaminated 104 (99.0) 104 (100)
Contaminated 1 (1.0) 0 (0)
Exeresis of other organs, n (%) 8 (7.6) 8 (7.7)
*P = 0.034.
Table 3 Summary of perioperative parameters
HA/CMC
powder (n = 105)
No adhesion
barrier (n = 104)
Estimated blood loss in mL,
mean ± SD
116.5 ± 197.7 81.6 ± 95.8
Administration of blood
products, n (%)
7 (6.7) 3 (2.9)
Blood sediments in units,
mean ± SD
2.0 ± 1.0 1.7 ± 0.6
Perioperative lavage, n (%) 73 (69.5) 73 (70.2)
Intraperitoneal 58 (79.5) 54 (74.0)
Intraluminal 4 (5.5) 2 (2.7)
Intraperitoneal and
intraluminal
11 (15.1) 17 (23.3)
Type of intraperitoneal lavage,
n (%)
Localized to intervention site 52 (76.5) 54 (77.1)
Whole cavity 16 (23.5) 16 (22.9)
Use of povidone-iodine
antiseptic irrigation, n (%)
19 (18.6) 23 (22.8)
Intraperitoneal 4 (21.1) 5 (21.7)
Intraluminal 12 (63.2) 14 (60.9)
Intraperitoneal and
intraluminal
3 (15.8) 4 (17.4)
Drain, n (%) 50 (47.6) 49 (47.1)
Vacuum, n (%) 37 (74.0) 37 (75.5)
Number of drains, mean ± SD 1.1 ± 0.3* 1.6 ± 1.5
Surgery duration in minutes,
mean ± SD
216.2 ± 87.1 203.2 ± 81.6
Postoperative oxygen therapy,
n (%)
69 (65.7) 56 (53.8)
*P = 0.021.
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was higher in the HA/CMC powder group than in the
no adhesion barrier group in patients with cancer (33%
vs. 17% and 16% vs. 6%, respectively; significance not
tested). Similarly, adverse events were more frequent in
the HA/CMC powder group versus the no adhesion bar-
rier group in patients with Crohn’s disease and ulcerative
colitis (Table 6; significance not tested).
Subgroup analysis also indicated a greater frequency of
adverse events among patients who had undergone pre-
vious abdominal/pelvic surgery than in those who had
not in both groups; however, the rate of adverse events
and serious adverse events was higher in the HA/CMC
powder group than in the no adhesion barrier group,
regardless of previous abdominal/pelvic surgery status
(data not shown).
Risk factor analysis
For the serious adverse events risk factor analysis, the
covariates included were age, smoking status, smoking
frequency, use of corticoids, surgical risk (National
Nosocomial Infections Surveillance Index; NNIS), previouscancer, fluorouracil used during the most recent chemo-
therapy and abdominal or pelvic radiation therapy admin-
istration. The probability of a serious adverse event was
greater in the HA/CMC powder versus the no adhesion
barrier group (OR = 4.08; 95% CI, 1.67–9.95; P = 0.002),
in younger patients (for age in years, OR = 0.94; 95% CI,
0.91–0.98; P = 0.002), and in patients who smoked fre-
quently (OR = 1.06; 95% CI, 1.02–1.10; P = 0.006). The
probability of a serious adverse event was also greater in
patients with a higher level of surgical risk: NNIS index 0
vs. ‒1 (OR = 1.33; 95% CI, 0.53–3.36; P = 0.027) and NNIS
index 1 vs. ‒1 (OR = 9.87; 95% CI, 1.82–53.53; P = 0.027),
in those with previous cancer (OR = 3.46; 95% CI, 1.02–
11.70; P = 0.046) and in those having used fluorouracil
during their last chemotherapy (OR = 7.12; 95% CI, 1.52–
33.42; P = 0.013).
For the deep SSIs risk factor analysis, age and smoking
frequency were included as covariates. The probability
for a deep SSI was greater in younger patients (for age
in years OR = 0.97; 95% CI, 0.94–1.00; P = 0.0362) and
Table 4 Summary of deaths, adverse events, and serious
adverse events (events occurring on or after the day of




barrier (n = 104)
Deaths 1 (1.0) 1 (1.0)
Any adverse event*, n (%) 66 (62.9)† 41 (39.4)
Any adverse event
considered severe, n (%)§
14 (13.3) 5 (4.8)
Most frequently reported
adverse events, n (%)§
Hyperthermia 6 (5.7) 3 (2.9)
Incision site abscess 5 (4.8) 3 (2.9)
Pelvic abscess 5 (4.8) 2 (1.9)
Urinary tract infection 5 (4.8) 1 (1.0)
Anastomotic fistula 4 (3.8) 4 (3.8)
Abdominal wall abscess 4 (3.8) 2 (1.9)
Ileus 3 (2.9) 2 (1.9)
Urinary retention 3 (2.9) 1 (1.0)
At least 1 serious adverse event,
n (%)
29 (27.6)† 11 (10.6)
Any serious adverse event
considered severe, n (%)§
9 (8.6) 3 (2.9)
Serious adverse events
occurring in ≥2 patients in
either group, n (%)§




Septic shock 1 (1.0) 2 (1.9)
Peritonitis 2 (1.9) 3 (2.9)
Ileus 3 (2.9) 0




*All adverse events coded according to the Medical Dictionary for Regulatory
Activities version 11.0.
†P <0.001 vs. no adhesion barrier group.
§Statistical significance not tested.
Table 5 Overall frequency of SSIs and serious SSIs, and







At least 1 SSI, n (%) 22 (21.0) 15 (14.4) 0.216
Deep 13 (12.4) 8 (7.7) 0.260
Incisional 13 (12.4) 7 (6.7) 0.165
At least 1 serious SSI,
n (%)
13 (12.4) 9 (8.7) 0.380
Deep 12 (11.4) 8 (7.7) 0.359
Incisional 2 (1.9) 1 (1.0) 1.000
All SSIs, n (%)
Infections and
infestations
20 (19.0) 11 (10.6) –
Incision site
abscess
5 (4.8) 3 (2.9) –
Pelvic abscess 5 (4.8) 2 (1.9) –
Abdominal wall
abscess
4 (3.8) 2 (1.9) –
Abdominal abscess 4 (3.8) 0 –
Incision site
infection
1 (1.0) 2 (1.9) –
Abscess intestinal 1 (1.0) 1 (1.0) –
Abdominal
infection
1 (1.0) 0 –
Bacteraemia 1 (1.0) 0 –
Postoperative
abscess
1 (1.0) 0 –
Septic shock 0 1 (1.0) –
Subcutaneous
abscess




6 (5.7) 4 (3.8) –
Anastomotic fistula 4 (3.8) 4 (3.8) –
Gastrointestinal
anastomotic leak
1 (1.0) 0 –
Incision site
complication
1 (1.0) 0 –
Gastrointestinal
disorders
2 (1.9) 5 (4.8) –
Peritonitis 2 (1.9) 3 (2.9) –
Colonic fistula 0 1 (1.0) –
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1.01–1.09; P = 0.010). No significant effect of treatment
was observed (OR = 0.58; 95% CI, 0.22–1.53; P = 0.269).Gastrointestinal
inflammation
0 1 (1.0) –
Shown by system organ class and preferred term.
–, Statistical significance not tested.
SSI, Surgical site infection.Ease of use and reliability
HA/CMC powder was considered to be manageable by
nurses in 98% (103/105) of procedures, based on ease
of use assessment (Figure 2A). Surgeons considered
HA/CMC powder manageable and reliable in 94% (99/
105) and 79% (83/105) of procedures, respectively
(Figure 2A,B).Discussion
In this exploratory study evaluating safety outcomes,
there were statistically significant differences between
the HA/CMC powder and the no adhesion barrier
Table 6 Frequency of adverse events, serious adverse
events, and serious SSIs by preoperative diagnosis
Preoperative diagnosis HA/CMC
powder (n = 105)
No adhesion
barrier (n = 104)
Cancer, n (%)
Adverse event 35 (33.3) 18 (17.3)
Serious adverse event 17 (16.2) 6 (5.8)
Serious SSI 4 (3.8) 5 (4.8)
Diverticulosis, n (%)
Adverse event 11 (10.5) 12 (11.5)
Serious adverse event 2 (1.9) 2 (1.9)
Serious SSI 2 (1.9) 2 (1.9)
Crohn’s disease, n (%)
Adverse event 7 (6.7) 2 (1.9)
Serious adverse event 4 (3.8) 1 (1.0)
Serious SSI 4 (3.8) 1 (1.0)
Ulcerative colitis, n (%)
Adverse event 5 (4.8) 4 (3.8)
Serious adverse event 3 (2.9) 1 (1.0)
Serious SSI 2 (1.9) 0
Polyp (no cancer), n (%)
Adverse event 4 (3.8) 4 (3.8)
Serious adverse event 1 (1.0) 1 (1.0)
Serious SSI 0 0
Endometriosis
Adverse event 1 (1.0) 1 (1.0)
Serious adverse event 1 (1.0) 0
Serious SSI 1 (1.0) 0
Polyposis
Adverse event 1 (1.0) 0
Serious adverse event 0 0
Serious SSI 0 1 (1.0)
Other
Adverse event 2 (1.9) 0
Serious adverse event 1 (1.0) 0
Serious SSI 0 0
SSI, Surgical site infection.
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adverse events (P <0.001). The occurrence of abdomino-
pelvic abscess was more frequent in the HA/CMC
powder group than in the no adhesion barrier group, al-
though there were no statistically significant differences
between groups in the frequency of SSIs or serious SSIs.
Surgeons considered HA/CMC powder easy to use and
reliable, and nurses also considered HA/CMC powder to
be manageable in the majority of procedures. Based on
the observed safety findings, the use of HA/CMCpowder is no longer being pursued in colorectal laparo-
scopic surgery.
The most frequent types of adverse events were those
often encountered in patients undergoing colorectal or
intestinal resection (‘infections and infestations’ and
‘gastro-intestinal disorders’). Among the adverse events
and serious adverse events that were considered by in-
vestigators to be related to treatment, there was not one
particular type of event or safety issue that was more
frequently reported than others. Frequency appeared to
be independent of the quantity of HA/CMC powder
applied. There was a trend towards a higher frequency
of adverse events in patients with cancer versus other
aetiologies, and a higher frequency of adverse events in
the HA/CMC powder group versus the no adhesion bar-
rier group in patients with cancer and those with inflam-
matory pathologies, although the study was not powered
to detect a significant difference for such a subgroup
analysis. As this was an exploratory study, no sample
size calculation was made, but the enrolment of approxi-
mately 100 patients per group would have provided a
95% CI of 25.6 to 44.4 for the detected difference, based
on an expected overall rate of serious adverse events of
35% [21].
Other studies report that SSIs occur following colorec-
tal surgery with a frequency ranging from 5% to 45%
[25-33]; the frequency of SSIs observed in this study falls
within this range. The risk factor analysis in our study
found no significant effect of treatment on risk for deep
SSIs. Factors that appeared to be associated with a
greater risk were lower age and frequent smoking. There
was a significant treatment effect on risk of serious ad-
verse events; other factors that appeared to be associated
with a greater risk were lower age, frequent smoking,
high level of surgical risk, previous cancer, and having
used fluorouracil during the last chemotherapy. How-
ever, given the exploratory design of this study, these
results must be considered with caution.
The findings of our study were unexpected given that
no safety issues were identified in a pilot study by Fossum
et al. assessing the use of HA/CMC powder in lapa-
roscopic myomectomy [20]. In their study, Fossum et al.
observed no overall difference in adverse event frequency
between the HA/CMC powder and the no adhesion
barrier groups (67% vs. 60%, respectively), and only one
patient experienced a serious adverse event (leukaemia, in
the no adhesion barrier group). No adverse events directly
related to HA/CMC powder were identified, as de-
termined by the surgeon, and there were no reports of
SSIs or intra-abdominal abscess. Furthermore, in animal
models, HA/CMC powder has been shown to be effective
in preventing adhesions without affecting wound healing
[18,19]. In a rat model of anastomotic healing, there were
no statistically significant differences between the HA/
AB
Figure 2 Ease of use and reliability. (A) Ease of use of HA/CMC powder, as assessed by surgeons and nurses; (B) Reliability of HA/CMC
powder, as assessed by surgeons. Overall manageability/reliability rates determined by overall number of cases scoring 3 or 4 on a 4-point scale
(3 = easy or good, 4 = very easy or very good). For multi-component items, all were required to achieve a score of 3 or 4.
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ber of deaths or short-term complications of abscess for-
mation, bowel obstruction, proximal colonic dilatation,
and wound dehiscence [19].
In the present study, an important consideration was
that the patient population enrolled had a high level of
comorbidity and a high probability of postoperative mor-
bidity. This population was intended to be heteroge-
neous, comprising a broad range of patients undergoing
various abdominal surgeries for a variety of diagnoses,
including cancer. The risk of postoperative infection is
high in patients undergoing gastrointestinal surgery as
a result of opening the bowel, whereas gynaecologic
surgery is usually a ‘clean’ (Class I) wound in comparison
[34]. Although direct comparison with other studies is
not possible, the overall rate of adverse events in the no
adhesion barrier group in this study (39%) was similar tooverall postoperative comorbidity rates in prospective
studies of open or laparoscopic colorectal surgery (~25%
to 35%) [21,35]. However, this does not explain the sig-
nificantly higher frequency of adverse events and serious
adverse events in the HA/CMC powder group versus
the no adhesion barrier group. Intraoperative and peri-
operative parameters that differed between groups were
adhesiolysis and manual anastomosis (both performed
more frequently in the HA/CMC powder group), num-
ber of drains (lower in the HA/CMC powder group),
and mean duration of surgery (longer in the HA/CMC
powder group).
As the safety of the film formulation has been confirmed
in clinical studies of gynaecological and abdominal surgery
[13,14,36,37], the powder formulation of HA/CMC used
in this study is likely to be an important contributing fac-
tor for the increased frequency of adverse events and
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new bowel anastomosis with HA/CMC film adhesion bar-
rier increased the risk of anastomotic leak and related
events such as fistula, peritonitis, abscess, and sepsis [24],
possibly by interfering with anastomosis healing; this prac-
tice is therefore contraindicated. For adhesion barriers
with a liquid or gel formulation, greater diffusion of prod-
uct across the peritoneal surface may play a role in in-
creasing adverse event risk as a result of application
occurring away from the wound site. Gels may also have a
propensity to pool away from the wound site. A study of
0.5% ferric hyaluronate gel adhesion barrier in open colo-
rectal surgery was suspended owing to significantly greater
morbidity versus the control group (distilled water, 65%
vs. 27%; P = 0.031). There was a higher rate of anasto-
motic dehiscence (5/17 vs. 1/15, respectively; not signifi-
cant) [34] but investigators were unable to determine
whether anastomotic healing was disrupted directly by the
adhesion barrier or by infection associated with gel use.
Furthermore, icodextrin 4% fluid is indicated for use only
in patients undergoing gynaecological laparoscopic adhe-
siolysis in the USA owing to occurrence of serious compli-
cations following laparotomy and bowel resection/repair
[38]. Pre-clinical data suggested that HA/CMC powder
demonstrated more rapid dissolution and wider diffusion
than HA/CMC film [19], with a greater capacity for fluid
absorption and release of a higher concentration of poly-
mer into solution within the first few hours of hydration
than the equivalent amount of HA/CMC film [18]. As ap-
plication of HA/CMC film to anastomoses is contra-
indicated owing to the potential for an increase in
anastomotic leak-related events [24], great care was taken
in our study to practise avoidance of anastomoses with
HA/CMC powder. Nevertheless, due to the potential for
greater diffusion of the powder formulation, the authors
speculate that migration away from the application site to
anastomoses could have occurred in some cases. Further-
more, over-hydration of the HA/CMC powder might have
resulted in pooling of the resulting gel away from the
application site, raising the possibility of migration onto
an anastomosis or provision of a nidus for abscess; such
migration to anastomoses might increase the rate of SSIs.
There is no current evidence of a biological effect of
HA/CMC [39-41], although hyaluronan is known to pro-
mote cell proliferation and migration [42]. Histological
analysis of tissues from pre-clinical studies indicated that
macrophage response and rate of remesothelialisation
appeared to be similar for both film and powder formula-
tions [18]. There may be potential for powder and gel for-
mulations to act as sites of origin for abscess formation,
and/or to be associated with septic complications [19]. An
animal study assessing the effect of adhesion barriers on
the progression of bacterial infection in the peritoneum
found that HA/CMC films had no effect when comparedwith control groups (saline), whereas some modified gel
formulations appeared to increase mortality [43]. Fur-
thermore, testing of HA/CMC powder in a rat model of
sepsis involving simultaneous exposure to variable doses
of Escherichia coli and sterile caecal contents identi-
fied a safety signal on repeat testing (unpublished data,
Genzyme Biosurgery), suggesting adverse effects in the
presence of active infection or gross caecal contamination.
Pre-clinical studies observed an infection potentiation
resulting from a physical interaction of HA/CMC powder
with caecal material and bacteria during the initial stages
of hydration within the first 4 h of implantation (unpub-
lished data, Genzyme Biosurgery). Although our study
excluded patients with pathology requiring class IV con-
tamination surgery and those with abdominal abscesses
and/or peritonitis or abdominal cavity infection, it is
possible that in some patients the presence of HA/CMC
powder in combination with luminal contents resulted in
adverse events owing to peritoneal bacterial contamination.
The main limitation of this trial is its exploratory
nature and lack of efficacy assessment. The study popu-
lation enrolled was a heterogeneous and difficult-to-treat
population with a high risk of morbidity and a broad
range of aetiologies; therefore, these results cannot be
extrapolated to other patient populations. The key
strength of the study was the care taken to standardize
the application technique according to the instructions
provided. The findings suggest that the observed safety
signals are most likely related to the specific formulation
(powder); therefore, these results should not be extrapo-
lated to other formulations of adhesion barriers.
Conclusions
This exploratory study found significantly higher rates of
adverse events and serious adverse events in the HA/CMC
powder group compared with the no adhesion barrier
group, indicating a global safety signal in the laparoscopic
application of HA/CMC powder in colorectal and small
bowel resection. Thus, further development of HA/CMC
powder is no longer being pursued for use in patients
undergoing colorectal and small bowel laparoscopic sur-
gery, given that this population has an elevated risk for
postoperative comorbidity.
Abbreviations
CI: Confidence interval; HA/CMC: Hyaluronic acid/carboxymethylcellulose;
NNIS: National Nosocomial Infections Surveillance Index; OR: Odds ratio;
SSIs: Surgical site infections.
Competing interests
This study was sponsored by Sanofi (formerly Genzyme Corporation),
Cambridge, MA, USA. All study sites received compensation in support of
patient enrolment and principal investigators were reimbursed for travel and
accommodation expenses related to investigator meetings by the study
sponsor. The article processing charge was paid by the study sponsor. SVB
received fees from Genzyme/Sanofi as a member of the steering committee
of the present trial and received reimbursement from Genzyme/Sanofi
Berdah et al. Trials 2014, 15:413 Page 11 of 12
http://www.trialsjournal.com/content/15/1/413for attending the 8th Congrès Francophone de Chirurgie Digestive et
Hépato-Biliaire (SFCD-ACHBT), 28–30 November 2012, Paris. CM received
fees from Genzyme/Sanofi as a member of the steering committee of the
present trial and a further European trial, received an educational grant from
Genzyme/Sanofi for providing an anti-adhesion barriers literature review, and
received speaker fees from Genzyme/Sanofi relating to the 8th Congrès
Francophone de Chirurgie Digestive et Hépato-Biliaire (SFCD-ACHBT), 28–30
November 2012, Paris and the 114th Congress of the Association Française
de Chirurgie, 3–5 October 2012, Paris. CD, YP, CL, EC, and NH have no
additional interests to disclose. ELPF is an employee of Sanofi (formerly
Genzyme Corporation). J-JD received funding from Sanofi (formerly Genzyme
Corporation) in 2009 in relation to a previous study.
Authors’ contributions
SVB acted as study co-ordinator and principal investigator, participated in
the design of the study, was involved as a study steering committee
member, enrolled patients and collected data, was involved in the analysis
and interpretation of the data, and drafted the manuscript. CM participated
in the design of the study, was involved as a study steering committee
member and in the analysis and interpretation of the data and critical
revision of the manuscript. CD, CL, and EC enrolled patients and collected
data, were involved in the interpretation of the data and critical revision of
the manuscript. YP and NH acted as principal investigators, enrolled patients
and collected data, and were involved in the interpretation of the data
and critical revision of the manuscript. ELPF acted as the medical project
manager, participated in the design of the study, and was involved in the
analysis and interpretation of the data and critical revision of the manuscript.
J-JD participated in the design of the study, was involved as a study steering
committee member, was involved in the analysis and interpretation of the
data, and drafted the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The authors acknowledge the contributions to this study of the following
co-investigators: Pr Michel Scotté, Hôpital Charles Nicolle, Rouen; Dr Hugues
Levard, Institut Mutualiste Montsouris, Paris; Pr Jean Gugenheim, Hôpital de
l’Archet, Nice; Pr Olivier Glehen, Centre Hospitalier Lyon-Sud, Pierre-Bénite;
Dr Guillaume Meurette and Pr Paul-Antoine Lehur, Hôpital Hôtel-Dieu,
Nantes; Dr Alexandre Rault, Hôpital Haut-Lévêque, Bordeaux; Dr Mohamed
Saïd Sbaï Idrissi, Centre Hospitalier Simone Veil, Eaubonne; Pr Philippe Wind,
Hôpital Avicenne, Bobigny; Dr Elie Chouillard, Centre Hospitalier Intercommunal
de Poissy-Saint Germain en Laye, Poissy (acting on behalf of iNOELS – the
Intercontinental Society of Natural Orifice, Endoscopic, and Laparoscopic
Surgery); and Pr Pierre Verhaeghe, Hôpital Amiens Nord, Amiens. The authors
also acknowledge Dr Sylvie Marlier-Bonnot, Sanofi, Saint-Germain en Laye,
France for her role in overseeing the study. Mrudula Donepudi PhD, Sanofi,
Cambridge, MA, USA, provided constructive input during manuscript
development. Editorial/writing support for the preparation of this manuscript
was provided by Helen Varley PhD CMPP, Envision Custom Solutions, Horsham,
UK, funded by Sanofi. The authors, however, were fully responsible for all
content and editorial decisions and received no financial support or other form
of compensation related to the development of the paper. This study
(NCT00813397) was funded by Sanofi (formerly Genzyme Corporation),
Cambridge, MA, USA.
Author details
1Chirurgie Digestive, Hôpital Nord, CERC (Centre d’Enseignement et de
Recherche Chirurgical), Aix-Marseille Université, Chemin des Bourrellys, 13915
Marseille, Cedex 20, France. 2Chirurgie Digestive et Générale, Hôpital Claude
Huriez, Centre Hospitalier Régional Universitaire, 2 Avenue Oscar Lambret,
59037 Lille, Cedex, France. 3Institut Mutualiste Montsouris, 42 Boulevard
Jourdan, 75674 Paris, Cedex 14, France. 4Chirurgie Colorectale, Hôpital
Beaujon, 100 Boulevard du Général Leclerc, 92110 Clichy, France. 5Chirurgie
Générale et Digestive, Hôpital Saint André, 1 Rue Jean Burguet, 33000
Bordeaux, France. 6Chirurgie Digestive et Endocrinienne, Centre Hospitalier
Lyon-Sud, Chemin du Grand Revoyet, 69310 Pierre-Bénite, France. 7Centre
Hospitalier Régional Universitaire de Tours, Avenue de la République, 37170
Chambray-lès-Tours, France. 8Sanofi (Genzyme), 33-35 Boulevard de la Paix,
78105 Saint-Germain-en-Laye, Cedex, France. 9Chirurgie Générale et
Digestive, Hôpital Pitié Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris,
France.Received: 30 April 2014 Accepted: 8 October 2014
Published: 27 October 2014References
1. Ouaïssi M, Gaujoux S, Veyrie N, Denève E, Brigand C, Castel B, Duron JJ,
Rault A, Slim K, Nocca D: Post-operative adhesions after digestive surgery:
their incidence and prevention: review of the literature. J Visc Surg 2012,
149:e104–114.
2. Diamond MP, Wexner SD, DiZereg GS, Korell M, Zmora O, Van Goor H,
Kamar M: Adhesion prevention and reduction: current status and future
recommendations of a multinational interdisciplinary consensus
conference. Surg Innov 2010, 17:183–188.
3. Miller G, Boman J, Shrier I, Gordon PH: Etiology of small bowel
obstruction. Am J Surg 2000, 180:33–36.
4. Duron JJ, Hay JM, Msika S, Gaschard D, Domergue J, Gainant A, Fingerhut A:
Prevalence and mechanisms of small intestinal obstruction following
laparoscopic abdominal surgery: a retrospective multicenter study.
French Association for Surgical Research. Arch Surg 2000, 135:208–212.
5. O'Connor DB, Winter DC: The role of laparoscopy in the management of
acute small-bowel obstruction: a review of over 2,000 cases. Surg Endosc
2012, 26:12–17.
6. Ten Broek RP, Issa Y, Van Santbrink EJ, Bouvy ND, Kruitwagen RF, Jeekel J,
Bakkum EA, Rovers MM, Van Goor H: Burden of adhesions in abdominal
and pelvic surgery: systematic review and met-analysis. BMJ 2013,
347:f5588.
7. Coleman MG, McLain AD, Moran BJ: Impact of previous surgery on time
taken for incision and division of adhesions during laparotomy. Dis Colon
Rectum 2000, 43:1297–1299.
8. Van Der Krabben AA, Dijkstra FR, Nieuwenhuijzen M, Reijnen MM,
Schaapveld M, Van Goor H: Morbidity and mortality of inadvertent
enterotomy during adhesiotomy. Br J Surg 2000, 87:467–471.
9. Di Saverio S, Coccolini F, Galati M, Smerieri N, Biffl WL, Ansaloni L, Tugnoli G,
Velmahos GC, Sartelli M, Bendinelli C, Fraga GP, Kelly MD, Moore FA,
Mandala V, Mandala S, Masetti M, Jovine E, Pinna AD, Peitzman AB,
Leppaniemi A, Sugarbaker PH, Van Goor H, Moore EE, Jeekel J, Catena F:
Bologna guidelines for diagnosis and management of adhesive small
bowel obstruction (ASBO): 2013 update of the evidence-based
guidelines from the world society of emergency surgery ASBO working
group. World J Emerg Surg 2013, 8:42.
10. Ten Broek RP, Kok-Krant N, Bakkum EA, Bleichrodt RP, Van Goor H: Different
surgical techniques to reduce post-operative adhesion formation: a
systematic review and meta-analysis. Hum Reprod Update 2013, 19:12–25.
11. Dowson HM, Bong JJ, Lovell DP, Worthington TR, Karanjia ND, Rockall TA:
Reduced adhesion formation following laparoscopic versus open
colorectal surgery. Br J Surg 2008, 95:909–914.
12. Polymeneas G, Theodosopoulos T, Stamatiadis A, Kourias E: A comparative
study of postoperative adhesion formation after laparoscopic vs open
cholecystectomy. Surg Endosc 2001, 15:41–43.
13. Ten Broek RP, Stommel MW, Strik C, Van Laarhoven CJ, Keus F, Van Goor H:
Benefits and harms of adhesion barriers for abdominal surgery: a
systematic review and meta-analysis. Lancet 2014, 383:48–59.
14. Becker JM, Dayton MT, Fazio VW, Beck DE, Stryker SJ, Wexner SD, Wolff BG,
Roberts PL, Smith LE, Sweeney SA, Moore M: Prevention of postoperative
abdominal adhesions by a sodium hyaluronate-based bioresorbable
membrane: a prospective, randomized, double-blind multicenter study.
J Am Coll Surg 1996, 183:297–306.
15. Vrijland WW, Tseng LN, Eijkman HJ, Hop WC, Jakimowicz JJ, Leguit P, Stassen
LP, Swank DJ, Haverlag R, Bonjer HJ, Jeekel H: Fewer intraperitoneal
adhesions with use of hyaluronic acid-carboxymethylcellulose membrane:
a randomized clinical trial. Ann Surg 2002, 235:193–199.
16. Hashimoto D, Hirota M, Yagi Y, Baba H: Hyaluronate carboxymethylcellulose-
based bioresorbable membrane (Seprafilm) reduces adhesion under the
incision to make unplanned re-laparotomy safer. Surg Today 2012,
42:863–867.
17. Fazio VW, Cohen Z, Fleshman JW, Van Goor H, Bauer JJ, Wolff BG, Corman
M, Beart RW Jr, Wexner SD, Becker JM, Monson JR, Kaufman HS, Beck DE,
Bailey HR, Ludwig KA, Stamos MJ, Darzi A, Bleday R, Dorazio R, Madoff RD,
Smith LE, Gearhart S, Lillemoe K, Gohl J: Reduction in adhesive small-
bowel obstruction by Seprafilm adhesion barrier after intestinal
resection. Dis Colon Rectum 2006, 49:1–11.
Berdah et al. Trials 2014, 15:413 Page 12 of 12
http://www.trialsjournal.com/content/15/1/41318. Greenawalt KE, Colt MJ, Corazzini RL, Syrkina OL, Jozefiak TH: Remote
efficacy for two different forms of hyaluronate-based adhesion barriers.
J Invest Surg 2012, 25:174–180.
19. Sheldon HK, Gainsbury ML, Cassidy MR, Chu DI, Stucchi AF, Becker JM: A
sprayable hyaluronate/carboxymethylcellulose adhesion barrier exhibits
regional adhesion reduction efficacy and does not impair intestinal
healing. J Gastrointest Surg 2012, 16:325–333.
20. Fossum GT, Silverberg KM, Miller CE, Diamond MP, Holmdahl L:
Gynecologic use of Sepraspray Adhesion Barrier for reduction of
adhesion development after laparoscopic myomectomy: a pilot study.
Fertil Steril 2011, 96:487–491.
21. Alves A, Panis Y, Mathieu P, Mantion G, Kwiatkowski F, Slim K: Postoperative
mortality and morbidity in French patients undergoing colorectal
surgery: results of a prospective multicenter study. Arch Surg 2005,
140:278–283. Discussion 284.
22. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR: Guideline for
prevention of surgical site infection, 1999. Hospital Infection Control
Practices Advisory Committee. Infect Control Hosp Epidemiol 1999,
20:250–278. Quiz 279–280.
23. Burns JW, Colt MJ, Burgees LS, Skinner KC: Preclinical evaluation of
Seprafilm bioresorbable membrane. Eur J Surg Suppl 1997, 577:40–48.
24. Beck DE, Cohen Z, Fleshman JW, Kaufman HS, Van Goor H, Wolff BG: A
prospective, randomized, multicenter, controlled study of the safety of
Seprafilm adhesion barrier in abdominopelvic surgery of the intestine.
Dis Colon Rectum 2003, 46:1310–1319.
25. Romy S, Eisenring MC, Bettschart V, Petignat C, Francioli P, Troillet N:
Laparoscope use and surgical site infections in digestive surgery.
Ann Surg 2008, 247:627–632.
26. Wick EC, Gibbs L, Indorf LA, Varma MG, Garcia-Aguilar J: Implementation of
quality measures to reduce surgical site infection in colorectal patients.
Dis Colon Rectum 2008, 51:1004–1009.
27. Serra-Aracil X, Garcia-Domingo MI, Pares D, Espin-Basany E, Biondo S, Guirao
X, Orrego C, Sitges-Serra A: Surgical site infection in elective operations
for colorectal cancer after the application of preventive measures.
Arch Surg 2011, 146:606–612.
28. Tang R, Chen HH, Wang YL, Changchien CR, Chen JS, Hsu KC, Chiang JM,
Wang JY: Risk factors for surgical site infection after elective resection of
the colon and rectum: a single-center prospective study of 2,809
consecutive patients. Ann Surg 2001, 234:181–189.
29. Kwaan MR, Sirany AM, Rothenberger DA, Madoff RD: Abdominal wall
thickness: is it associated with superficial and deep incisional surgical
site infection after colorectal surgery? Surg Infect (Larchmt) 2013,
14:363–368.
30. Drosdeck J, Harzman A, Suzo A, Arnold M, Abdel-Rasoul M, Husain S:
Multivariate analysis of risk factors for surgical site infection after
laparoscopic colorectal surgery. Surg Endosc 2013, 27:4574–4580.
31. Anthony T, Murray BW, Sum-Ping JT, Lenkovsky F, Vornik VD, Parker BJ,
McFarlin JE, Hartless K, Huerta S: Evaluating an evidence-based bundle for
preventing surgical site infection: a randomized trial. Arch Surg 2011,
146:263–269.
32. Blumetti J, Luu M, Sarosi G, Hartless K, McFarlin J, Parker B, Dineen S, Huerta
S, Asolati M, Varela E, Anthony T: Surgical site infections after colorectal
surgery: do risk factors vary depending on the type of infection
considered? Surgery 2007, 142:704–711.
33. Crolla RM, van der Laan L, Veen EJ, Hendriks Y, Van Schendel C, Kluytmans J:
Reduction of surgical site infections after implementation of a bundle of
care. PLoS One 2012, 7:e44599.
34. Tang CL, Jayne DG, Seow-Choen F, Ng YY, Eu KW, Mustapha N: A randomized
controlled trial of 0.5% ferric hyaluronate gel (Intergel) in the prevention of
adhesions following abdominal surgery. Ann Surg 2006, 243:449–455.
35. Neudecker J, Klein F, Bittner R, Carus T, Stroux A, Schwenk W: Short-term
outcomes from a prospective randomized trial comparing laparoscopic
and open surgery for colorectal cancer. Br J Surg 2009, 96:1458–1467.
36. Diamond MP: Reduction of adhesions after uterine myomectomy by
Seprafilm membrane (HAL-F): a blinded, prospective, randomized,
multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril
1996, 66:904–910.
37. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H: Efficacy of Seprafilm as an
adhesion prevention barrier in cesarean sections. Obstet Gynecol
Treatment 2005, 91:557–561.38. Adept Adhesion Reduction Solution (4% Icodextrin). Information for Prescribers.
[http://www.baxterbiosurgery.com/us/resources/pdfs/adept/ADEPT_
Instructions_For_Use.pdf]
39. Gago LA, Saed GM, Chauhan S, Elhammady EF, Diamond MP: Seprafilm
(modified hyaluronic acid and carboxymethylcellulose) acts as a physical
barrier. Fertil Steril 2003, 80:612–616.
40. Lim R, Morrill JM, Lynch RC, Reed KL, Gower AC, Leeman SE, Stucchi AF,
Becker JM: Practical limitations of bioresorbable membranes in the
prevention of intra-abdominal adhesions. J Gastrointest Surg 2009,
13:35–41. Discussion 41–32.
41. Otake K, Uchida K, Yoshiyama S, Inoue M, Okita Y, Watanabe H, Inoue Y, Mohri
Y, Miki C, Kusunoki M: Effects of a hyaluronate-carboxymethylcellulose
membrane (Seprafilm) on human polymorphonuclear neutrophil functions.
J Surg Res 2008, 149:243–249.
42. Toole BP, Wight TN, Tammi MI: Hyaluronan-cell interactions in cancer and
vascular disease. J Biol Chem 2002, 277:4593–4596.
43. Tzianabos AO, Cisneros RL, Gershkovich J, Johnson J, Miller RJ, Burns JW,
Onderdonk AB: Effect of surgical adhesion reduction devices on the
propagation of experimental intra-abdominal infection. Arch Surg 1999,
134:1254–1259.
doi:10.1186/1745-6215-15-413
Cite this article as: Berdah et al.: A multicentre, randomised, controlled
trial to assess the safety, ease of use, and reliability of hyaluronic acid/
carboxymethylcellulose powder adhesion barrier versus no barrier in
colorectal laparoscopic surgery. Trials 2014 15:413.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
